[Click e-Stock] "GC Genome Accelerates High Growth in Multi-Cancer Early Detection... Strong Potential to Lead U.S. Market"

GC Genome, a genomics-based precision medicine company, is emerging as a growth driver on the back of its expanding multi-cancer early detection business and expectations for entry into the U.S. market. With the expansion of the cancer early detection market and a rapidly growing customer base, there are projections that the company's performance growth will accelerate further.

Choi Jaeho, a researcher at Briars Insight, stated in a recent report, "This is a pivotal moment when inevitable high growth and various investment opportunities are coming to the fore."

Founded in 2013, GC Genome provides clinical genome testing services throughout the life cycle. The company offers over 300 types of testing services, ranging from obstetric testing for mothers and fetuses to precision cancer diagnostics, genetic testing for rare diseases, and artificial intelligence (AI)-based multi-cancer early screening tests.

Researcher Choi commented, "GC Genome appears to be the only company offering comprehensive clinical genome analysis testing services," and added, "As a subsidiary of the GC Group, it boasts superior business infrastructure compared to competitors and holds the number one market share in each field."

The company's performance trajectory is also becoming increasingly differentiated. GC Genome achieved an operating profit turnaround in the first quarter of this year, which is typically a seasonal off-peak period. This is evaluated as a striking result compared to other major domestic genetic testing companies that continue to post losses.

Choi noted, "Given the rapidly increasing number of client companies and the company's scalability, the likelihood of posting a quarterly loss in the future is virtually zero," adding, "On the contrary, the company is expected to maintain its high-growth trajectory."

The overhang supply, which had been a burden since the company's listing, has also been largely resolved. He analyzed, "Compared to domestic genetic testing firms such as 3billion and Genomictree, GC Genome remains significantly undervalued," and assessed, "This is a favorable time to expect a strong upward trend in the share price."

The market is particularly focusing on the growth of the multi-cancer early detection (MCED) service, 'iCanSearch.' iCanSearch is a testing service capable of diagnosing approximately 10 types of cancer early with just 10ml of blood. It has achieved an average sensitivity of 84.5% and a specificity of 94.5%.

The speed of client acquisition is also notable. Based on medical institutions, the number of clients increased from 35 in 2024 to over 110 in the first quarter of this year. During the same period, the number of tests more than doubled from 700 in the first quarter of last year to 1,400 in the first quarter of this year. In the first quarter of this year, the company also secured new corporate clients such as LG Group, Kia, Korean Air, and Korea Hydro & Nuclear Power.

Choi stated, "By 2026, the number of clients is expected to reach around 160, and the number of tests to exceed 10,000," adding, "On average, the number of tests conducted by each retained client continues to increase every year. This is why high growth is inevitable."

The greatest growth momentum is cited as entry into the U.S. market. GC Genome is currently pursuing U.S. market entry with its pancreatic cancer early detection product 'PANC-CERCH.' This product is reported to have achieved a test sensitivity of 95.0% and specificity of 95.6%. The company completed specimen collection in the first quarter of this year and plans to apply for the U.S. Food and Drug Administration (FDA) Breakthrough Device Designation (BDD) in the fourth quarter of this year.

Choi emphasized, "Currently, there are no standardized early screening services for pancreatic cancer in the U.S.," and added, "Based on the performance of its test, GC Genome's potential to capture the U.S. market is extremely high."

This content was produced with the assistance of AI translation services.